Biocartis Group NV announced it has signed a license, development and commercialization agreement with GeneproDx, for the development of GeneproDx’s novel genomic test ThyroidPrint on Biocartis’ rapid and easy to use molecular diagnostics platform Idylla. Under the terms of the agreement, GeneproDx will take the lead in the development of the IdyllaThyroidPrint test, whereas Biocartis will be responsible for the distribution of the ThyroidPrint on Idylla through its growing commercial infrastructure of Idylla™ instruments across the globe.